Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1802768 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $59.18Day −1.32%Mkt cap $33.4BP/E (FY) 33.2×1Y +62.2%Off 52W high −2.1%Vol (1Y) 22.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 3,187 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Fair value (model)$21.24 |
| Implied upside−64.1% |
| Valuation confidenceLOW |
| Price impliesAGGRESSIVE · 22.4% growth |
| Short interest2.1% of sh out |
| Days to cover4.4d |
| 13F net flow (QoQ)−1.79% |
| Top-10 13F concentration53.8% |
| Next report (est.)2026-08-05 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)33.2× |
| Sales (TTM)$2.44B |
| YTD+54.6% |
| 1Y+62.2% |
| 3Y+104.2% |
| 5Y+74.0% |
| 10Y+3087.4% |
| Since incept. (ann.)+17.4% |
Total return through 2026-07-29 · series begins 2011-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)22.8% |
| Ann. volatility (3Y)23.4% |
| Sharpe (1Y)2.28 |
| Sharpe (3Y)1.15 |
| Max drawdown (1Y)−7.4% |
| Max drawdown (3Y)−20.7% |
| Beta (3Y vs SPY)0.56 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| MORGAN STANLEY | 43.6M | $2.1B | 7.72% | −21.2% |
| Capital International Investors | 35.0M | $1.7B | 6.20% | +12.5% |
| BlackRock, Inc. | 25.9M | $1.2B | 4.59% | −1.1% |
| FMR LLC | 25.2M | $1.2B | 4.46% | −4.3% |
| BAILLIE GIFFORD & CO | 16.2M | $775M | 2.86% | −5.0% |
| Swedbank AB | 11.6M | $556M | 2.05% | −3.0% |
| STATE STREET CORP | 11.0M | $527M | 1.95% | +3.2% |
| Capital World Investors | 8.0M | $386M | 1.42% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | $0.67 | +21.8% | $630.6M | +11.0% |
| 2025-12-31 | 2026-02-11 | — | — | $622.0M | +4.8% |
| 2025-09-30 | 2025-11-05 | $0.67 | −44.6% | $609.3M | +7.9% |
| 2025-06-30 | 2025-08-06 | $0.07 | −69.6% | $578.7M | +7.7% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Financial Royalty Assets 95% · Royalty Income Other 5%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
| Earnings (TTM)$826.3M |
| Net margin32.4% |
| ROIC8.9% |
| EPS growth 3Y161.1% |
| Sales growth 3Y2.1% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
